Table 1.
Patient characteristics of F-IR cohort (n = 220) and VL/LR and F-IR cohort (n = 647)
| Variables | F-IR only | VL/LR and F-IR |
|---|---|---|
| No. patients, n (%) | 220 (25) | 647 (75) |
| Age | ||
| Median (Q1, Q3) | 61 (56−66) | 60 (55−65) |
| Race, n (%) | ||
| African American | 11 (5) | 27 (4) |
| Caucasian | 138 (63) | 383 (59) |
| Other | 20 (9) | 64 (10) |
| Unknown | 51 (23) | 173 (27) |
| Biopsy stage, n (%) | ||
| cT1 | 147 (67) | 474 (73) |
| cT2 | 73 (33) | 173 (27) |
| Biopsy grade group, n (%) | ||
| Grade group 1 | 83 (38) | 510 (79) |
| Grade group 2 | 137 (62) | 137 (21) |
| % positive biopsy cores | ||
| Median (Q1, Q3) | 23.5 (14.3, 33.3) | 25 (15.4, 35.7) |
| PSA | ||
| Median (Q1, Q3) | 5.86 (4.6, 9.29) | 5.47 (4.22, 7) |
| NCCN, n (%) | ||
| F-IR | 220 (100) | 220 (34) |
| VL/LR | 427 (66) | |
| CAPRA, n (%) | ||
| 0 | 2 (1) | 25 (4) |
| 1 | 22 (10) | 209 (32) |
| 2 | 93 (42) | 271 (42) |
| 3 | 86 (39) | 120 (19) |
| 4 | 17 (8) | 17 (3) |
| Unavailable | 5 (1) | |
| Time from biopsy to RP (month) | ||
| Median (Q1, Q3) | 3 (2.37, 3) | 3 (2.73, 3) |
| RP stage, n (%) | ||
| pT2c or less | 162 (74) | 492 (76) |
| pT3a | 52 (24) | 141 (22) |
| pT3b | 6 (3) | 14 (2) |
| RP grade group, n (%) | ||
| Grade group 1 | 56 (25) | 273 (42) |
| Grade group 2 | 132 (60) | 309 (48) |
| Grade group 3 | 27 (12) | 52 (8) |
| Grade group 4 | 4 (2) | 9 (1) |
| Grade group 5 | 1 (<1) | 4 (1) |
| Positive surgical margins, n (%) | ||
| Absent | 180 (82) | 531 (82) |
| Present | 40 (18) | 116 (18) |
| Lymph node invasion, n (%) | ||
| Absent | 220 (100) | 644 (99.5) |
| Present | 3 (0.5) | |
| BCR follow-up (year) for censored patients | ||
| Median (Q1, Q3) | 2.79 (1.33, 5.72) | 3.49 (1.47, 6.8) |
F-IR NCCN favorable-intermediate risk, VL/LR NCCN very low/low risk, PSA prostate-specific antigen, NCCN National Comprehensive Cancer Network, CAPRA Cancer of the Prostate Risk Assessment, RP radical prostatectomy, BCRbiochemical recurrence